MedPath

Adipose Tissue Pre and Post Bariatric Surgery

Conditions
Obesity
Interventions
Procedure: Bariatric surgery
Other: Blood sampling
Other: Blood pressure
Other: Anthropometric measurements
Other: Body composition
Other: Resting metabolic rate
Other: Food intake
Procedure: Adipose tissue biopsy
Registration Number
NCT05304325
Lead Sponsor
Institut de Recherches Cliniques de Montreal
Brief Summary

Published data suggest that inflammation and fibrosis of adipose tissue could be factors favoring the development of insulin resistance in obese individuals and that a decrease in the activity of the AMP-activity kinase protein (AMPK) could lead to these dysfunctions. However, very few data are available in humans.

There is also growing interest in persistent organic pollutants (POPs) as a cardiometabolic and type 2 diabetes (T2D) risk factor. There is some evidence to suggest that POPs directly contribute to lipid metabolism dysfunction and insulin resistance. Additionally, POPs are stocked in adipose tissue. The accumulation of POPs in adipose tissue therefore limits their bioavailability to other organs, thus reducing their systemic toxicity. It has been observed that a large amplitude weight loss leads to a significant increase in POPs in the blood.

The goal of this project is to identify adipose tissue factors/dysfunctions that contribute to insulin resistance and type 2 diabetes associated with obesity in humans and thus raise avenues for screening and treatment of these metabolic complications. More specifically, the objectives are:

* To study the relationship between AMPK, fibrosis and inflammation of adipose tissue and their role in the development of insulin resistance and T2D associated with obesity;

* To examine the relationship between POPs and the cardiometabolic profile.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
98
Inclusion Criteria
  1. Awaiting bariatric surgery
  2. BMI ≥ 35 kg/m2 without cardiometabolic complications or ≥ 30 kg/m2 if presence of type 2 diabetes or hypertension
  3. ≥ 18 years old
  4. Non smoker
  5. Sedentary (less than 3 hours of regular physical activity per week)
Exclusion Criteria
  1. Type 1 diabetes
  2. Acute event in the last 3 months (myocardial infarction, cerebrovascular hemorrhage or transient cerebral ischemia, unstable angina, peripheral vascular disease, revascularization or angioplasty, recent hospitalization for more than 4 days)
  3. Infection in the last month (fever, antibiotics treatment)
  4. Cancer in the last 3 years
  5. Chronic inflammatory disease
  6. Pharmacologic treatment (any medication affecting glucose metabolism (except those for diabetes), hypotensive medication unless stable dose for at least 1 month, lipid-lowering medication unless stable dose for at least 1 month)
  7. Uncontrolled disease of pituitary or thyroid gland
  8. Bleeding disorders
  9. Alcohol or drug abuses
  10. Claustrophobia

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Obese insulin-resistantFood intake-
Obese with type 2 diabetesAnthropometric measurements-
Obese with type 2 diabetesBody composition-
Obese insulin-sensitiveResting metabolic rate-
Obese with type 2 diabetesBlood pressure-
Obese with type 2 diabetesBariatric surgery-
Obese with type 2 diabetesBlood sampling-
Obese with type 2 diabetesResting metabolic rate-
Obese insulin-sensitiveBariatric surgery-
Obese with type 2 diabetesFood intake-
Obese insulin-resistantResting metabolic rate-
Obese insulin-resistantAdipose tissue biopsy-
Obese insulin-sensitiveAnthropometric measurements-
Obese insulin-resistantBlood pressure-
Obese insulin-sensitiveAdipose tissue biopsy-
Obese insulin-resistantBlood sampling-
Obese insulin-resistantAnthropometric measurements-
Obese with type 2 diabetesAdipose tissue biopsy-
Obese insulin-sensitiveBlood pressure-
Obese insulin-sensitiveBody composition-
Obese insulin-resistantBody composition-
Obese insulin-sensitiveBlood sampling-
Obese insulin-sensitiveFood intake-
Obese insulin-resistantBariatric surgery-
Primary Outcome Measures
NameTimeMethod
Adipose tissue fibrosis using qRT-PCR, immunoblotting, histochemistry and immunohistochemistry6 months after bariatric surgery
Secondary Outcome Measures
NameTimeMethod
Food quality using the Food Frequency Questionnaire6 months after bariatric surgery
Persistant organic pollutants measured by high-resolution chromatography combined with high-resolution mass spectrometry6 months after bariatric surgery
AMP-activated protein kinase6 months after bariatric surgery
Calory intake6 months after bariatric surgery
Inflammation in adipose tissue using qRT-PCR, immunoblotting and immunohistochemistry6 months after bariatric surgery

Trial Locations

Locations (1)

Institut de recherches cliniques de Montréal

🇨🇦

Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath